Lambert Aurélien, Conroy Thierry, Ducreux Michel
Medical Oncology Department, Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France; Université de Lorraine, Nancy, France.
Medical Oncology Department, Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France; Université de Lorraine, Nancy, France.
Semin Oncol. 2021 Feb;48(1):47-56. doi: 10.1053/j.seminoncol.2021.02.002. Epub 2021 Feb 23.
Pancreatic cancer is still one of the most lethal cancers with a reported 5-year relative survival rate of approximatively 9% and medical treatment remains a major challenge. Systemic treatment is recommended in every setting: resectable, borderline resectable, locally advanced and metastatic. Yet, few groundbreaking changes in practice have occurred in the last 30 years compared to other cancers and new treatments options are highly desirable. Most treatment approaches using chemotherapy have failed to improve patients' life expectancy and the few therapies finally found to have statistically significant benefit actually have modest clinical impact. It is becoming imperative to find new paths for improvement, such as encapsulated agents, new generation targeted therapies and treatments directed against the tumor microenvironment. We report here the new drugs of interest in pancreatic cancer and analyze the most recent failures.
胰腺癌仍然是最致命的癌症之一，据报道其5年相对生存率约为9%，医学治疗仍然是一项重大挑战。在各种情况下都推荐进行全身治疗：可切除、边界可切除、局部晚期和转移性。然而，与其他癌症相比，在过去30年里临床实践中几乎没有发生突破性变化，因此非常需要新的治疗选择。大多数使用化疗的治疗方法都未能提高患者的预期寿命，而最终发现具有统计学显著益处的少数疗法实际上临床影响有限。寻找新的改进途径变得势在必行，例如封装药物、新一代靶向疗法以及针对肿瘤微环境的治疗。我们在此报告胰腺癌领域值得关注的新药，并分析最近的失败案例。
